Doctor Mariam Elmegaard

Back

Doctor Mariam Elmegaard

Gentofte University Hospital, Copenhagen (Denmark)

Member of:

Presentations

Implementation of sodium-glucose co-transporter 2 inhibitors in patients with heart failure through a new digital strategy (EMAIL-HF): a randomised clinical trial study design

Event: ESC Congress 2024

Topic: Trial Design

Session: Cardiovascular risk prediction, mortality disparities, and equity in cardiology research: global insights

Access

Temporal trends in initiation of oral anticoagulants and stroke-free survival among elderly and very elderly patients with new onset atrial fibrillation - a 20-year perspective.

Event: ESC Congress 2024

Topic: Oral Anticoagulation

Session: Stroke risk management in atrial fibrillation registries: key take-home messages for clinicians

Access

Biochemical profiles and risk of cardiovascular events in patients withType 2 Diabetes: implications for choice of novel antihyperglycemic therapy

Event: ESC Congress 2023

Topic: Antidiabetic Pharmacotherapy

Session: Novel targets and treatments for heart diseases and diabetes

Access

Adherence and discontinuation of sglt2-inhibitors and glp1-r agonists in patients with type 2 diabetes with and without cardiovascular disease

Event: ESC Congress 2022

Topic: Antidiabetic Pharmacotherapy

Session: Anti-diabetic pharmacotherapy in clinical practice

Access

Risk of heart failure associated with thiazide diuretics compared with calcium channel blockers in patients with type 2 diabetes: a nationwide nested case-control study

Event: ESC Congress 2020

Topic: Prevention

Session: Pharmacological Interventions To Treat and Prevent Acute Heart Failure

Access

Cardiovascular risk profiles and outcomes in patients with type 2 diabetes - Implications for choice of new diabetes therapies

Event: ESC Congress 2019

Topic: Epidemiology

Session: The right glucose-lowering drugs for the right patient

Access

Development of heart failure in type 2 diabetes: ischemic heart disease, end stage renal disease or hypertension and diabetes? a nationwide cohort study

Event: ESC Congress 2018

Topic: Epidemiology, Prognosis, Outcome

Session: Heart failure: the nemesis of Diabetes

Access

ESC 365 is supported by

Explore sponsored resources

Doctor Mariam Elmegaard Follow

Contributor content

Implementation of sodium-glucose co-transporter 2 inhibitors in patients with heart failure through a new digital strategy (EMAIL-HF): a randomised clinical trial study design

Temporal trends in initiation of oral anticoagulants and stroke-free survival among elderly and very elderly patients with new onset atrial fibrillation - a 20-year perspective.

Biochemical profiles and risk of cardiovascular events in patients withType 2 Diabetes: implications for choice of novel antihyperglycemic therapy

Adherence and discontinuation of sglt2-inhibitors and glp1-r agonists in patients with type 2 diabetes with and without cardiovascular disease

Risk of heart failure associated with thiazide diuretics compared with calcium channel blockers in patients with type 2 diabetes: a nationwide nested case-control study

Cardiovascular risk profiles and outcomes in patients with type 2 diabetes - Implications for choice of new diabetes therapies

Development of heart failure in type 2 diabetes: ischemic heart disease, end stage renal disease or hypertension and diabetes? a nationwide cohort study

ESC 365 is supported by

Doctor Mariam Elmegaard